Fax: (310) 825-7795
Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma
A “split-sample” study
Article first published online: 13 APR 2009
Copyright © 2009 American Cancer Society
Volume 117, Issue 3, pages 167–173, 25 June 2009
How to Cite
Sullivan, P. S., Nooraie, F., Sanchez, H., Hirschowitz, S., Levin, M., Rao, P. N. and Rao, J. (2009), Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma. Cancer Cytopathology, 117: 167–173. doi: 10.1002/cncy.20026
- Issue published online: 11 JUN 2009
- Article first published online: 13 APR 2009
- Manuscript Accepted: 5 JAN 2009
- Manuscript Revised: 12 DEC 2008
- Manuscript Received: 26 SEP 2008
- bladder neoplasms;
- fluorescence in situ hybridization;
- monoclonal antibodies;
ImmunoCyt (uCyt) and UroVysion are ancillary studies that may aid in the detection of urothelial carcinoma in urine specimens. We compared ImmunoCyt and UroVysion to urine cytology in the ability to detect recurrent urothelial carcinoma.
Single voided urine samples were obtained from 100 patients who had a previous history of bladder cancer. All patients underwent cystoscopy immediately after urine sample collection. Forty-one cystoscopically suspicious lesions were biopsied. Urine samples were divided and processed blindly and independently in 3 different laboratories for ImmunoCyt, UroVysion, and urine cytology (ThinPrep method).
Of the 41 cystoscopically positive cases, most cystoscopy findings showed multiple tumors that were papillary and less than 1 cm. Biopsies showed many low-grade tumors (54%). Overall sensitivity of cytology for low- and high-grade urothelial cell carcinoma was 15% and 27%, whereas ImmunoCyt was 62% and 91% and UroVysion was 8% and 18%, respectively. Overall specificity of cytology was 97%, whereas ImmunoCyt was 63% and UroVysion was 90%.
ImmunoCyt is more sensitive than either cytology or UroVysion in detecting low-grade tumors. Both cytology and UroVysion have comparable specificity in cystoscopically negative cases. Whereas ImmunoCyt may improve the cytological detection of recurrent bladder cancer, UroVysion may be used as a confirmatory test for either cytology or ImmunoCyt. Cancer (Cancer Cytopathol) 2009. © 2009 American Cancer Society.